10-Q: Carmell Corporation Reports Q3 2024 Results, Focuses on Skincare and Cost Reduction

Carmell Corporation's Q3 2024 results show a strategic shift towards cosmetic skincare, reduced R&D spending, and ongoing efforts to manage liquidity amidst a net loss.

Summary

• Carmell Corporation reported its financial results for the third quarter of 2024, highlighting a strategic pivot towards cosmetic skincare products.
• The company's net sales for the quarter were $20,519, with a gross profit of $15,679.
• Operating expenses totaled $1,435,468, which included $331,806 in research and development costs, a significant decrease from the previous year.
• The company experienced a net loss from continuing operations of $2,878,481 for the quarter.
• For the nine months ended September 30, 2024, net sales were $32,839, with a gross profit of $27,707.
• The net loss from continuing operations for the nine-month period was $9,736,181.
• The company's cash balance stood at $1,137,325 as of September 30, 2024, with an accumulated deficit of $67,957,379.
• Carmell is exploring additional capital raising, haircare product development, and out-licensing of R&D programs to improve liquidity.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments like the launch of new products and a new CEO, but the overwhelming financial challenges, including significant losses, low cash reserves, and a going concern warning, lead to a negative sentiment.

Positives

• The company has successfully launched its first five cosmetic skincare products and plans to launch seven more in the next six months.
• Research and development expenses have been significantly reduced due to a strategic realignment.
• The appointment of a new CEO with experience in the beauty and wellness industries may bring new opportunities.
• The AxoBio Disposition resulted in a gain of $1,534,479.
• The company has secured $2,687,225 in net proceeds from a private placement.

Negatives

• The company reported a net loss from continuing operations of $2,878,481 for the quarter and $9,736,181 for the nine months.
• The company has an accumulated deficit of $67,957,379 and a cash balance of only $1,137,325.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is facing ongoing litigation related to convertible notes.
• The company's disclosure controls and procedures were deemed not effective as of September 30, 2024 due to a material weakness in internal controls.

Risks

• The company's ability to continue as a going concern is in doubt due to its current financial situation.
• The company may need to raise additional capital through equity or debt issuances, which may not be available on acceptable terms.
• Ongoing litigation related to convertible notes could have a material adverse effect on the company's financial condition.
• Global economic conditions, including political instability and conflicts, could negatively impact the company's business and financial results.
• The company's disclosure controls and procedures were not effective as of September 30, 2024 due to a material weakness in internal controls.

Future Outlook

The company is focused on commercializing its cosmetic skincare products, exploring haircare product development, and seeking additional capital and out-licensing opportunities to improve its financial position.

Management Comments

• The Board appointed Kendra Bracken-Ferguson as Chief Executive Officer of the Company effective as of July 30, 2024.
• Rajiv Shukla resigned from his position as our Chief Executive Officer but continues to serve as Executive Chairman of the Board.
• Management anticipates that revenue from the commercialization of its cosmetic skincare products and the anticipated cost savings will assist us in extending our cash runway.

Industry Context

The company's shift towards cosmetic skincare aligns with the growing demand for bio-based and natural skincare products. The company is also exploring the haircare market, which is another growing segment in the personal care industry. The company's focus on professional care providers and discerning retail consumers is a common strategy in the premium skincare market.

Comparison to Industry Standards

• Carmell's revenue is very low compared to established players in the skincare industry, such as Estee Lauder, L'Oreal, and Unilever, which report billions in revenue annually.
• The company's R&D spending, while reduced, is still significant for a company of its size, especially when compared to companies that have already commercialized their products.
• The company's net loss and negative cash flow are concerning and indicate a need for significant improvement in financial performance.
• The company's focus on the Carmell Secretome is a unique approach, but its success will depend on market acceptance and the ability to scale production.
• The company's legal issues and material weakness in internal controls are also concerning and need to be addressed to ensure long-term stability.

Management Changes

Legal Proceedings

• Puritan Partners LLC filed a complaint against the company alleging breach of contract and other claims related to convertible notes and warrants.
• The company is defending itself against this litigation.

Related Party Transactions

• The placement agent for the private placement is a related party, as a member of the Board is a managing partner of the placement agent.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential cost-cutting measures and restructuring.
• Customers may be affected by the company's ability to continue operations and deliver products.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company plans to launch seven additional cosmetic skincare products in the next six months.
• The company will continue to explore raising additional capital.
• The company will focus on the development and commercialization of haircare products.
• The company will explore out-licensing certain research and development programs.
• The company will address the material weakness in internal controls.

Key Dates

Keywords

cosmetic skincare, Carmell Secretome, financial results, liquidity, research and development, AxoBio Disposition, going concern, capital raise, litigation, internal controls